Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has increased by 2458674 compared to its previous closing price of 2.11. However, the company has seen a 3.24% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-24 that NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint that was filed against Maravai on March 3, 2025 with a Class Period from August 7, 2024 and February 24, 2025. Our investigation concerns whether the board of directors of Maravai have breached their fiduciary duties to the company.
Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?
Additionally, the 36-month beta value for MRVI is 0.25. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRVI is 103.98M and currently, short sellers hold a 13.15% ratio of that float. The average trading volume of MRVI on June 25, 2025 was 2.07M shares.
MRVI’s Market Performance
MRVI stock saw a decrease of 3.24% in the past week, with a monthly decline of -2.83% and a quarterly a decrease of -0.45%. The volatility ratio for the week is 3.96%, and the volatility levels for the last 30 days are 4.63% for Maravai LifeSciences Holdings Inc (MRVI). The simple moving average for the last 20 days is 1.48% for MRVI stock, with a simple moving average of -51.82% for the last 200 days.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Robert W. Baird repeating the rating for MRVI by listing it as a “Neutral.” The predicted price for MRVI in the upcoming period, according to Robert W. Baird is $3 based on the research report published on February 26, 2025 of the current year 2025.
Goldman gave a rating of “Sell” to MRVI, setting the target price at $4.25 in the report published on December 05th of the previous year.
MRVI Trading at 6.43% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -77.77% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRVI starting from ORESHACK KURT, who sale 25,000 shares at the price of $5.03 back on Jan 31 ’25. After this action, ORESHACK KURT now owns 167,618 shares of Maravai LifeSciences Holdings Inc, valued at $125,750 using the latest closing price.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -1.1 for the present operating margin
- 0.37 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.67. The total capital return value is set at -0.3. Equity return is now at value -45.75, with -13.53 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -8.85.
Currently, EBITDA for the company is -156.92 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.44. The receivables turnover for the company is 8.49for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.96.
Conclusion
In conclusion, Maravai LifeSciences Holdings Inc (MRVI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
